Log inTry free

Palvella Therapeutics (PVLA) stock

Market cap $1.9B

$128.00
-3.15%

Market closed. Prices as of today's close.

Quality Score
1
Below Average
In its industry
#117of 300
Biotech

PVLA's Quality Score fell 6 points on Tue, Oct 6, to 1. Its daily swings widened (4 chart checks stopped). 1 more reason, for Pro members.

Next2H 2026“…malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026”Filing with regulators · 8-K, Aug 4

Follow PVLA's trial news. Pro members can get an alert when Palvella Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when PVLA files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Holding it back

A $42M loss.

2 more reasons behind PVLA's 1, for Pro members

What's next for PVLA, and how long its cash lasts

From Palvella Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026”Filing with regulators · 8-K, Aug 4

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
LOTUPhase 2 · Recruiting · 15 people · main data estimated Aug 2027 · NCT07552077

3 more trials, 5 more milestones and 39 filings, for Pro members.

Cash runway

The company says its cash lasts into 2H 2027 (8-K, Jan 29).

That is the company's own estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Jan 2, 2026)
  • At-the-market share sales program (S-3, filed Jan 2, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Operating Officer Kathleen Goin sold 4,302 shares on Sep 16, under a planned sale. 13 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Wes Kaupinen buys or sells

For Pro members: every trade, and Wes Kaupinen’s 13 filings and quotes.

Get an optional alert when PVLA files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why PVLA beats the market

Palvella Therapeutics returned +95% over the past year to the S&P 500's +17%; its 5 peers' median returned +99%.

Its 5 peers' median return over the past year was +99%, from +12% (Mirum Pharmaceuticals) to +121% (Travere Therapeutics).

Sources: Price history, Oct 5, 2026

1 more driver, the timeline, and the peer table, for Pro members

Why PVLA scores 1

Below AverageTransition, 0 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

Well below its own recent run. PVLA scores 1 today, against a median of 10 over its last 20 recorded sessions.

  • +2Long-term trend above a rising 200-⁠day average
  • −1Profit Lost $41.7M in the year to Dec 31, 2025, more than the $17.4M lost the year before, from the SEC filingRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Persistence adds

No effect today: Chart checks, Run-up, Size, Growth, Dilution, Cash flow, News, and Insider trades.

What every line is worth, and the reason behind it, on PVLA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:17 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, before the open

After its last 4 reports it closed +1.1% on average, higher 2 of 4 times.

What would turn PVLA's score around: 6 things, for Pro members

Alert me when PVLA's Quality Score turns up

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on PVLA and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Nothing is firing on PVLA right now

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on PVLA, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

How PVLA ranks in Biotech

PVLA is #117 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does PVLA report earnings, and what happens after?

Expected to report Wed Nov 11, before the open (in 36 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 4, 2026Before open-3.9%+8.0%+8.1%
May 7, 2026Before open-0.9%-13.0%-7.4%
Mar 31, 2026Before open+4.5%+12.6%+8.5%
Nov 10, 2025After close-5.2%-3.0%+1.7%

The gap is the next open against the close before the report; the reaction is where that session closed. PVLA closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading PVLA

PVLA insider trades

One insider sold $49K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellChristopher P. Kiritsy$49KDirectorat $157.00 on Sep 2, filed Sep 4

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

PVLA's officers and directors

Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.

See insider trades by person

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

29 employeesWayne, PApalvellatx.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of PVLA's score, with the points and the reason
  • All 14 checks on PVLA and on all 3,244 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on PVLA
BreakawaySep 4Christopher P. Kiritsy sold PVLA$49K at $157.00, filed Sep 4

What a filing on PVLA would have sent. Alerts are optional.

See all 14 checks on PVLASee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.